Dear NMUSERS,
I was wondering if anyone on this list has experience implementing analysis of
in-vitro data on drug synergy (combination of two anticancer drugs in different
concentrations) with the help of NONMEM, e.g. by the method of Chou and Talalay
(Cancer Research 70: 440-446 (2010)) or an
Hi Robert,
Just wondering: what drug are you modeling? A beta-blocker? An ACE inhibitor?
My gut feeling tells me you should also incorporate some feedback between drug
effects like blood pressure, heart rate and urine output with these drugs based
on their mode of action instead of considering
Dear Kok-Yong Seng,
Is the drug undergoing presystemic metabolism after oral administration? This
might explain some differences in metabolic rate constants before and after
oral administration. If your drug undergoes presystemic metabolism, metabolite
concentrations may appear earlier in the s
Hi Xinting ,
You might want to check out the PDF of the presentation of Justin Wilkins at
the PAGE in 2005: http://www.page-meeting.org/?abstract=769
By the way, in my experience this model does not really outperform a little
more simple method with a chain of transition/absorption compartments
Hi Paolo,
I've been recently thinking about this matter as well. I ultimately decided to
include all concentration data below the LOQ, if in the chromatogram they had a
signal to noise ratio of >5 (compared with blank plasma) and to estimate the
additive component of the residual error whenever
Hi Paolo,
Considering 2A:
The residual error model always should already account for a possible larger
residual error at lower concentrations. I think a combined proportional and
additive error model willfor this. If an additive component can't be estimated,
my gut feeling tells me fixing the
Dear Paolo,
The reduced bioavailability is most likely a result of increased,
however variable, pre-systemic metabolism which also correlates with
systemic clearance. Have you tried linking these together in your model,
e.g. with a well-stirred liver model (e.g. Gordi et al Br J Clin
Pharmacol. 20
Hi all,
I updated from OS X 10.7 to 10.8 yesterday and found my Nonmem/Pirana
installation not working anymore. Just wanted to share my experience
getting Nonmem 7.2 and Pirana 2.5.0 to work again.
1. OS X no longer supports X11, required for pirana. One should
therefore download XQuartz from x
Dear Shankar Lanke,
you can try modeling variable absorption with a chain of transit
compartments and estimating the mean absorption and to account for
interoccasion variability in relative oral bioavailability (e.g.
F1=1*EXP(ETA(1)).
Other things that you should account for with efavirenz in
Dear all,
Thanks for the many suggestions getting this to work. I got NONMEM
installed on OSX 10.7 lion as follows:
1. Enabled root access as described here:
http://www.macosliontips.com/tips/enable-root-account-in-mac-os-x-lion.h
tml
2. Created the folders /opt and /opt/nm7.2 manually
3. Inst
Dear Shankar,
As I read it, if your autoinduction is complete after 14 days, you do
not really have the data describing the autoinduction process, except
for a single trough sample, which is probably not enough considering the
inter-occasion variability in F and probably only a marginal or absent
Dear Shankar,
How rich is your dataset? In other words: do you have enough data
troughout the induction period to estimate the lagtime? You could, for
example try to fix the lagtime to a reasonable time and estimate the
inter-individual variability. Another way of estimating the
autoniduction is
Dear Nele,
Couldn't this be solved by simply turning on a flag after a certain time and
estimate a seperate residual error when this flag is turned on? Ofcourse you
can also code this flag in your dataset.
Rob
Van: owner-nmus...@globomaxnm.com [mailt
13 matches
Mail list logo